Slide Show: Highlights From the 2015 ASCO Breast Cancer Symposium

Slideshow
Conference|ASCO Breast Cancer Symposium

This slide show highlights some of the presentations that took place at the 2015 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium in San Francisco, September 25-27, 2015.

References:

  • Caggiano V, Parise C. Racial/ethnic disparities in HER2-positive breast cancer in the era of adjuvant trastuzmab. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 139.
  • Hong JJ, Seksenyan A, Yuan X. et al. TOX3 as a novel biomarker in luminal B breast cancer. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 130.
  • Yadav S, Fulbright J, Dreyfuss H,  et al. Outcomes of retesting BRCA-negative patients using multigene panels. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 23.
  • Shafaee MN, Gutierrez-Barrera AM, Lin HL, Arun B. Aromatase inhibitors and the risk of contralateral breast cancer in BRCA mutation carriers. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 3.
  • Hassan SN, Esch A, Heiser L, Gray JW. Biological indicators of response and resistance to PARP inhibition in BRCA wild-type breast cancer. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 125.
  • Chan A, Martin M, Von Minckwitz G. et al. Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial. Presented at the 2015 American Society of Clinical Oncology Breast Cancer Symposium; Abstract 117.

 

 

 

 

 

Recent Videos
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer. Antibody-drug conjugates are effective, but strategies such as better understanding the mechanisms of action may lead to enhanced care for patients with cancer.
ADCs demonstrate superior efficacy vs chemotherapy but maintain a similar efficacy profile that requires multidisciplinary collaboration to optimally treat.
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Nadunolimab Exhibits Comparable Efficacy Vs Chemotherapy Alone in TNBC

Roman Fabbricatore
December 5th 2025
Article

The safety profile of nadunolimab in patients with triple-negative breast cancer was consistent with its known profile, and no significant signals emerged.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

Giredestrant Exhibits DFS Improvement in Early-Stage Breast Cancer

Roman Fabbricatore
November 18th 2025
Article

According to the developers, giredestrant is the first oral SERD to display beneficial DFS in early-stage breast cancer in the adjuvant setting.

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Data from the ASCENT-07 trial show an early trend toward improved overall survival with sacituzumab govitecan vs chemotherapy.

Sacituzumab Govitecan Misses PFS End Point in Metastatic Breast Cancer

Russ Conroy
November 11th 2025
Article

Data from the ASCENT-07 trial show an early trend toward improved overall survival with sacituzumab govitecan vs chemotherapy.

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research

Ariana Pelosci
November 8th 2025
Article

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.